Objective:

To compare the clinical efficacy of Risankizumab (RZB) with Icotrokinra (ICO) in adult patients with moderate-to-severe psoriasis using a matching-adjusted indirect comparison (MAIC).

Approach:

• Study Design: This MAIC compares clinical efficacy between RZB and ICO in adult patients with moderate-to-severe psoriasis, utilizing individual patient data from phase 3 trials.
• Data Sources: Included studies were phase 3, multinational randomized controlled trials that enrolled adults with moderate-to-severe plaque psoriasis, with endpoints assessed primarily at week 16 and beyond.

Key Findings:

• AsignificantlyhigherproportionofpatientstreatedwithRZBachieved≥75%improvementinPASI(PASI75)comparedtoICO,withsimilartrendsobservedforPASI90,PASI100,Investigator’sGlobalAssessmentof0or1(IGA0/1),andIGA0.ResultsindicatethatRZBmayprovidegreaterclinicalefficacythanICOovera52-weekperiodbasedonindirectcomparisons.

Interpretation:

The findings suggest that RZB may be more effective than ICO in treating moderate-to-severe psoriasis, based on indirect comparisons.

Limitations:

• Theanalysisisbasedonindirectcomparisons,whichmaybesensitivetodifferencesinpopulationcharacteristics.OnlystudiespublishedbeforeMarch31,2026,wereincluded,whichmaylimitthecomprehensivenessofthedata.

Conclusion:

The study provides insights into the comparative efficacy of RZB and ICO for moderate-to-severe psoriasis.